greeksoup/ stocks
Stocks / United States / AMGN / Q4 FY2024

Amgen Inc. Q4 FY2024 results: revenue $9.1 billion, up 10.9% on the year

Amgen Inc. (AMGN) reported revenue of $9.1 billion for Q4 FY2024, the quarter ended 31 December 2024, up 10.9% on the same quarter a year earlier. Net income was $627 million, down 18.3% on the year, and diluted earnings per share $1.17. The figures are the company's own, from the 10-K it filed with the SEC on 14 February 2025.

Revenue$9.1 billionup 10.9%
Net income$627 milliondown 18.3%
Diluted EPS$1.17
QuarterQ4 FY2024ended 31 December 2024

The quarter, against the one before and a year earlier

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Revenue9,0868,5038,196+10.9%
Cost of revenue3,1123,3103,112+0.0%
Gross profit5,9745,1935,084+17.5%
Gross margin65.7%61.1%62.0%
Research and development1,7241,4501,534+12.4%
Selling, general and administrative1,8781,6252,274-17.4%
Operating income2,3112,0471,271+81.8%
Operating margin25.4%24.1%15.5%
Interest expense747776821-9.0%
Pre-tax income7823,101852-8.2%
Income tax15527185.0+82.4%
Effective tax rate19.8%8.7%10.0%
Net income6272,830767-18.3%
Net margin6.9%33.3%9.4%
Diluted EPS$1.17$5.22$1.42-17.6%

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Operating cash flow4,7713,571538+786.8%
Capital expenditure371257249+49.0%
Free cash flow4,4003,314289+1422.5%
Free cash flow margin48.4%39.0%3.5%
Depreciation and amortisation1,3971981,380+1.2%
Share-based compensation134136161-16.8%
Buybacksn/an/a0.0n/a
Dividends paid1,2051,2101,140+5.7%
Dividend per share$2.38$2.25$2.25+5.8%
Diluted shares, weighted541m542m538m+0.6%
Shares outstanding at period end537m538m535m+0.3%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Total assets91,83990,88397,154-5.5%
Cash and equivalents11,9739,01110,944+9.4%
Receivables6,7827,3177,268-6.7%
Inventory6,9987,3629,518-26.5%
Goodwill18,63718,65818,629+0.0%
Long-term debt60,09960,39864,613-7.0%
Operating lease liabilities673n/a691-2.6%
Shareholders' equity5,8777,5276,232-5.7%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue6,9038,1967,4478,3888,5039,0868,1499,1799,5579,8668,61810,054
Cost of revenue1,8063,1123,2003,2363,3103,1122,9683,0113,0822,9762,7442,811
Gross profit5,0975,0844,2475,1525,1935,9745,1816,1686,4756,8905,8747,243
Gross margin74%62%57%61%61%66%64%67%68%70%68%72%
R&D1,0791,5341,3431,4471,4501,7241,4861,7441,9002,1421,7191,868
SG&A1,3532,2741,8081,7851,6251,8781,6871,6911,7201,9521,6021,745
Operating income2,0211,2719911,9092,0472,3111,1782,6562,5262,7202,6663,514
Operating margin29%16%13%23%24%25%14%29%26%28%31%35%
Interest expense759821824808776747723694685653657673
Pre-tax income1,947852-68.07943,1017821,9731,5683,9211,5142,0842,768
Tax rate11%10%n/a6%9%20%12%9%18%12%13%14%
Net income1,730767-1137462,8306271,7301,4323,2161,3331,8192,375
Net margin25%9%-2%9%33%7%21%16%34%14%21%24%
Diluted EPS$3.22$1.42-$0.21$1.38$5.22$1.17$3.20$2.65$5.93$2.45$3.34$4.37
Operating cash flow2,7605386892,4593,5714,7711,3912,2804,6841,6032,1894,002
Capital expenditure248249230238257371411369436642712513
Free cash flow2,5122894592,2213,3144,4009801,9114,2489611,4773,489
Buybacks0.00.0n/an/an/an/an/an/an/an/an/an/a
Dividends paid1,1401,1401,2081,2091,2101,2051,2791,2801,2821,2831,3581,362
Shares outstanding535m535m536m537m538m537m538m538m538m539m540m541m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-K for the period ended 31 December 2024, filed 14 February 2025, accession 0000318154-25-000010: the filing on EDGAR. All of Amgen Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install